Ocumension climbs 7% on NMPA approval for implant productionMarket Movers·Oct 28, 2026 at 05:14 AM01477+0.52%
Ocumension Phase III Myopia Drug OT-101 Hits Primary Goal in China CohortTip Ranks·Oct 20, 2026 at 12:38 AM01477+0.52%
Ocumension Biopharma drops 2% in Hong Kong on glaucoma drug filingHK Stock Market Update·Sep 22, 2026 at 01:43 AM01477+0.52%
Nicox Announces NCX 470 NDA in China Accepted for ReviewGlobeNewswire·Sep 11, 2026 at 05:30 AM01477+0.52%
Ocumension says China NMPA accepts OT-301 glaucoma drug applicationPUBT·Sep 10, 2026 at 11:00 PM01477+0.52%